中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
12期
1067-1070
,共4页
刘兰涛%郭尚福%郎志芳%初彦辉%王洪伟%徐玉东
劉蘭濤%郭尚福%郎誌芳%初彥輝%王洪偉%徐玉東
류란도%곽상복%랑지방%초언휘%왕홍위%서옥동
雷公藤多苷%实验性自身免疫性重症肌无力%T细胞受体
雷公籐多苷%實驗性自身免疫性重癥肌無力%T細胞受體
뢰공등다감%실험성자신면역성중증기무력%T세포수체
Tripterygium glycosides%Experimental autoimmune myasthenia gravis%T cell receptor
目的：研究雷公藤多苷对实验性自身免疫性重症肌无力（ experimental autoimmune myasthenia gravis，EAMG）大鼠的治疗作用。方法：建立EAMG动物模型，依据Lennon评分法及体质量监测，初步评定雷公藤多苷对EAMG大鼠的治疗作用；并采用实时荧光定量聚合酶链式反应（ real?time polymerase chain reaction，RT?PCR）方法，检测完全弗氏佐剂组、EAMG模型组、雷公藤多苷治疗组大鼠胸腺及外周血单个核细胞T细胞受体（T?cell receptor，TCR）BV基因信使核糖核酸（mRNA）的表达情况。结果：雷公藤多苷可以改善EAMG大鼠肌无力症状，降低Lennon评分，增加大鼠体质量。 EAMG模型大鼠TCR BV基因表达谱呈现偏移，而雷公藤多苷治疗组大鼠的mRNA表达量有所下降，差异具有统计学意义（P＜0?05）。结论：雷公藤多苷能有效缓解EAMG大鼠的临床症状，能控制EAMG大鼠基因的偏移，可降低特异性活化的抗原反应性T细胞活性。
目的：研究雷公籐多苷對實驗性自身免疫性重癥肌無力（ experimental autoimmune myasthenia gravis，EAMG）大鼠的治療作用。方法：建立EAMG動物模型，依據Lennon評分法及體質量鑑測，初步評定雷公籐多苷對EAMG大鼠的治療作用；併採用實時熒光定量聚閤酶鏈式反應（ real?time polymerase chain reaction，RT?PCR）方法，檢測完全弗氏佐劑組、EAMG模型組、雷公籐多苷治療組大鼠胸腺及外週血單箇覈細胞T細胞受體（T?cell receptor，TCR）BV基因信使覈糖覈痠（mRNA）的錶達情況。結果：雷公籐多苷可以改善EAMG大鼠肌無力癥狀，降低Lennon評分，增加大鼠體質量。 EAMG模型大鼠TCR BV基因錶達譜呈現偏移，而雷公籐多苷治療組大鼠的mRNA錶達量有所下降，差異具有統計學意義（P＜0?05）。結論：雷公籐多苷能有效緩解EAMG大鼠的臨床癥狀，能控製EAMG大鼠基因的偏移，可降低特異性活化的抗原反應性T細胞活性。
목적：연구뢰공등다감대실험성자신면역성중증기무력（ experimental autoimmune myasthenia gravis，EAMG）대서적치료작용。방법：건립EAMG동물모형，의거Lennon평분법급체질량감측，초보평정뢰공등다감대EAMG대서적치료작용；병채용실시형광정량취합매련식반응（ real?time polymerase chain reaction，RT?PCR）방법，검측완전불씨좌제조、EAMG모형조、뢰공등다감치료조대서흉선급외주혈단개핵세포T세포수체（T?cell receptor，TCR）BV기인신사핵당핵산（mRNA）적표체정황。결과：뢰공등다감가이개선EAMG대서기무력증상，강저Lennon평분，증가대서체질량。 EAMG모형대서TCR BV기인표체보정현편이，이뢰공등다감치료조대서적mRNA표체량유소하강，차이구유통계학의의（P＜0?05）。결론：뢰공등다감능유효완해EAMG대서적림상증상，능공제EAMG대서기인적편이，가강저특이성활화적항원반응성T세포활성。
OBJECTIVE:To explore the therapeutic efficacy of tripterygium glycosides ( TG ) for experimental autoimmune myasthenia gravis( EAMG) . METHODS:The EAMG rat model was established. The therapeutic efficacy of tripterygium glycosides for EAMG in rats was evaluated by using Lennon scoring and body mass monitoring; the mRNA expression of the BV gene in thymus and in peripheral blood mononuclear cells T?cell receptor( T?cell receptor, TCR) were detected by quantitative real?time polymerase chain reaction ( RT?PCR ) in complete freund?s adjuvant group,EAMG model group and tripterygium glycosides treatment group. RESULTS: The use of tripterygium glycosides resulted in improvement of the clinical symptoms of myasthenia gravis, reduction of LennonLA score but increase of body mass. The TCR BV gene expression profiles in EAMG rat model presented offset, while the message RNA ( mRNA) expression in tripterygium glycosides group showed reduction ( P <0?05 ) . CONCLUSIONS:Treatment of EAMG with tripterygium glycosides effectively alleviated EAMG symptoms, prevent offset of TCR BV gene and reduce the activities of the specificity?activated antigen?reactive T cells.
